Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday. The Durham, NC-based company plans to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million.
Chimerix, which booked $34 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol CMRX. Chimerix initially filed confidentially on 1/30/2013. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal.
